ifosfamide - CISMeF

Preferred Label : ifosfamide;

MeSH definition : Positional isomer of CYCLOPHOSPHAMIDE which is active as an alkylating agent and an immunosuppressive agent.;

MeSH synonym : iso endoxan; isophosphamide; iso-endoxan; iphosphamide; isofosfamide;

MeSH hyponym : asta Z 4942; holoxan; NSC-109,724; NSC 109,724; NSC109,724; NSC-109724; NSC 109724; NSC109724;

MeSH CAS label : 2H-1,3,2-Oxazaphosphorin-2-amine, N,3-bis(2-chloroethyl)tetrahydro-, 2-oxide;

MeSH Related Number : 3778-73-2 (Ifosfamide);

Registry Number MeSH : 3778-73-2;

Wikipedia link : https://en.wikipedia.org/wiki/Ifosfamide;

Codes EINECS : 223-237-3;

Is substance : O;

UNII : UM20QQM95Y;

InChIKey : HOMGKSMUEGBAAB-UHFFFAOYSA-N;

Details

Origin ID

D007069;

UMLS CUI

C0020823;

ATC code(s)
- ifosfamide [ATC Code]
Allowable qualifiers
- administration and dosage [MeSH Qualifier]
- adverse effects [MeSH Qualifier]
- agonists [MeSH Qualifier]
- analogs and derivatives [MeSH Qualifier]
- analysis [MeSH Qualifier]
- antagonists and inhibitors [MeSH Qualifier]
- blood [MeSH Qualifier]
- cerebrospinal fluid [MeSH Qualifier]
- chemical synthesis [MeSH Qualifier]
- chemistry [MeSH Qualifier]
- classification [MeSH Qualifier]
- contraindications [MeSH Qualifier]
- economics [MeSH Qualifier]
- history [MeSH Qualifier]
- immunology [MeSH Qualifier]
- isolation and purification [MeSH Qualifier]
- metabolism [MeSH Qualifier]
- pharmacokinetics [MeSH Qualifier]
- pharmacology [MeSH Qualifier]
- poisoning [MeSH Qualifier]
- radiation effects [MeSH Qualifier]
- standards [MeSH Qualifier]
- supply and distribution [MeSH Qualifier]
- therapeutic use [MeSH Qualifier]
- toxicity [MeSH Qualifier]
- urine [MeSH Qualifier]
Automatic exact mappings (from CISMeF team)
- Ifosfamide [LOINC Challenge]
- Ifosfamide [ICHI extension code]
- pre dose ifosfamide [LOINC Challenge]
CISMeF manual mappings
- Ifosfamide poisoning (disorder) [SNOMED CT concept]
- ifosfamide [Substance BNPC]
Currated CISMeF NLP mapping
- Ifosfamide [ICD-11 Extension code]
- Ifosfamide [LOINC component]
- Ifosfamide [NCIt concept]
- Ifosfamide (substance) [SNOMED CT concept]
Pharmacological action(s)
- antineoplastic agents, alkylating [MeSH Descriptor]
Record concept(s)
- NSC-109,724 [MeSH concept]
- asta Z 4942 [MeSH concept]
- holoxan [MeSH concept]
- ifosfamide [MeSH concept]
Related MeSH Supplementary Concept(s)
- 4-hydroxyifosfamide [MeSH Supplementary Concept]
- 4-ketoifosfamide [MeSH Supplementary Concept]
- AVI protocol [MeSH Supplementary Concept]
- AVIP protocol [MeSH Supplementary Concept]
- BIC protocol [MeSH Supplementary Concept]
- BIP protocol [MeSH Supplementary Concept]
- CAMBO-VIP protocol [MeSH Supplementary Concept]
- CEOP-IMVP-Dexa regimen [MeSH Supplementary Concept]
- CIF protocol [MeSH Supplementary Concept]
- CIV protocol [MeSH Supplementary Concept]
- COSS-86 protocol [MeSH Supplementary Concept]
- DD1 protocol [MeSH Supplementary Concept]
- DICE protocol [MeSH Supplementary Concept]
- DIZE protocol [MeSH Supplementary Concept]
- EID protocol [MeSH Supplementary Concept]
- ENSG 3C protocol [MeSH Supplementary Concept]
- EVI protocol [MeSH Supplementary Concept]
- FADIP protocol [MeSH Supplementary Concept]
- FILM protocol [MeSH Supplementary Concept]
- FIM protocol [MeSH Supplementary Concept]
- G-IDEA protocol [MeSH Supplementary Concept]
- GIP protocol [MeSH Supplementary Concept]
- HELP protocol [MeSH Supplementary Concept]
- HOP protocol [MeSH Supplementary Concept]
- HR-2 protocol [MeSH Supplementary Concept]
- IAP protocol [MeSH Supplementary Concept]
- ICE protocol 1 [MeSH Supplementary Concept]
- ICE protocol 2 [MeSH Supplementary Concept]
- ICE protocol 3 [MeSH Supplementary Concept]
- ICE protocol 5 [MeSH Supplementary Concept]
- ICE protocol 6 [MeSH Supplementary Concept]
- IE protocol [MeSH Supplementary Concept]
- IEV protocol [MeSH Supplementary Concept]
- IEVM protocol [MeSH Supplementary Concept]
- IIVP-16 [MeSH Supplementary Concept]
- IMAP protocol [MeSH Supplementary Concept]
- IMEP protocol [MeSH Supplementary Concept]
- IMVP-16 protocol [MeSH Supplementary Concept]
- IVA protocol [MeSH Supplementary Concept]
- IVAC protocol [MeSH Supplementary Concept]
- IVAD protocol [MeSH Supplementary Concept]
- IVADIC regimen [MeSH Supplementary Concept]
- IVAM regimen [MeSH Supplementary Concept]
- IVEP protocol [MeSH Supplementary Concept]
- MAID protocol [MeSH Supplementary Concept]
- MAMI protocol [MeSH Supplementary Concept]
- MCP 842 regimen [MeSH Supplementary Concept]
- MICE regimen [MeSH Supplementary Concept]
- MIME protocol [MeSH Supplementary Concept]
- MINE protocol [MeSH Supplementary Concept]
- MINE regimen [MeSH Supplementary Concept]
- MINE-BOP protocol [MeSH Supplementary Concept]
- MINE-ESHAP protocol [MeSH Supplementary Concept]
- MINT protocol [MeSH Supplementary Concept]
- MIP protocol [MeSH Supplementary Concept]
- MIZE protocol [MeSH Supplementary Concept]
- MMIP protocol [MeSH Supplementary Concept]
- N-dechloroethylifosfamide [MeSH Supplementary Concept]
- NIP regimen [MeSH Supplementary Concept]
- NaPIM protocol [MeSH Supplementary Concept]
- OS 87 protocol [MeSH Supplementary Concept]
- PAVI protocol [MeSH Supplementary Concept]
- PETHEMA ALL-3-97 protocol [MeSH Supplementary Concept]
- PI protocol [MeSH Supplementary Concept]
- PIN protocol [MeSH Supplementary Concept]
- PRIME protocol [MeSH Supplementary Concept]
- RIME regimen [MeSH Supplementary Concept]
- SSG IX protocol [MeSH Supplementary Concept]
- TIC protocol [MeSH Supplementary Concept]
- TIP regimen [MeSH Supplementary Concept]
- VACIME protocol [MeSH Supplementary Concept]
- VAIA protocol [MeSH Supplementary Concept]
- VAIP protocol [MeSH Supplementary Concept]
- VIA protocol [MeSH Supplementary Concept]
- VIC-E protocol [MeSH Supplementary Concept]
- VIE protocol [MeSH Supplementary Concept]
- VIF protocol [MeSH Supplementary Concept]
- VIG protocol [MeSH Supplementary Concept]
- VIM-Bleo protocol [MeSH Supplementary Concept]
- VIM-D protocol [MeSH Supplementary Concept]
- VIM3 protocol [MeSH Supplementary Concept]
- VIM3-ARA C regimen [MeSH Supplementary Concept]
- VIMB protocol [MeSH Supplementary Concept]
- VIMP protocol [MeSH Supplementary Concept]
- VIP protocol 1 [MeSH Supplementary Concept]
- VIP protocol 2 [MeSH Supplementary Concept]
- VIP protocol 3 [MeSH Supplementary Concept]
- VIP regimen 2 [MeSH Supplementary Concept]
- VIP-B protocol [MeSH Supplementary Concept]
- VIP-E protocol [MeSH Supplementary Concept]
- VIP-VB protocol [MeSH Supplementary Concept]
- VIPP-BM protocol [MeSH Supplementary Concept]
- VPIV protocol [MeSH Supplementary Concept]
- VeIP protocol [MeSH Supplementary Concept]
- VlhP protocol [MeSH Supplementary Concept]
- acetaldoifosphamide [MeSH Supplementary Concept]
- beta-D-glucosylisophosphoramide mustard [MeSH Supplementary Concept]
- bromofosfamide [MeSH Supplementary Concept]
- carboxyifosfamide [MeSH Supplementary Concept]
- chlorobromofosfamide [MeSH Supplementary Concept]
- dechloroethylifosfamide [MeSH Supplementary Concept]
- hydroperoxyisophosphamide [MeSH Supplementary Concept]
- m-BOP protocol [MeSH Supplementary Concept]
- palifosfamide lysine [MeSH Supplementary Concept]
- phenylketoisophosphamide [MeSH Supplementary Concept]
- rizzoli IOR protocol [MeSH Supplementary Concept]
Semantic type(s)
- Organic Chemical [UMLS semantic type]
- Pharmacologic Substance [UMLS semantic type]
UMLS correspondences (same concept)
- Ifosfamide [ICD-11 Extension code]
- Ifosfamide [LOINC Challenge]
- Ifosfamide [LOINC component]
- Ifosfamide [NCIt concept]
- Ifosfamide (substance) [SNOMED CT concept]
- Product containing ifosfamide (medicinal product) [SNOMED CT concept]
- ifosfamide [ATC Code]
- ifosfamide [Substance BNPC]
Validated automatic mappings to BTNT
- ifosfamide [ATC Code]

Keyword's position in hierarchy(ies) :

Main resources

You can consult :

recommendations
documents concerning education
documents for patients